🇺🇸 SUCCIMER in United States

FDA authorised SUCCIMER on 30 January 1991 · 34 US adverse-event reports

Marketing authorisations

FDA — authorised 30 January 1991

  • Application: NDA019998
  • Marketing authorisation holder: RECORDATI RARE
  • Local brand name: CHEMET
  • Indication: CAPSULE — ORAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 8 reports (23.53%)
  2. Hypertension — 4 reports (11.76%)
  3. Skin Striae — 4 reports (11.76%)
  4. Weight Increased — 4 reports (11.76%)
  5. Blood Lead Increased — 3 reports (8.82%)
  6. Cushingoid — 3 reports (8.82%)
  7. Chromaturia — 2 reports (5.88%)
  8. Cough — 2 reports (5.88%)
  9. Dizziness — 2 reports (5.88%)
  10. Drug Ineffective For Unapproved Indication — 2 reports (5.88%)

Source database →

SUCCIMER in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is SUCCIMER approved in United States?

Yes. FDA authorised it on 30 January 1991; FDA has authorised it.

Who is the marketing authorisation holder for SUCCIMER in United States?

RECORDATI RARE holds the US marketing authorisation.